Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Toxicities of MM drug treatments

Ravi Vij • 15 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Carfilzomib Lenalidomide Olanzapine Panobinostat Pomalidomide Selinexor Thalidomide

Ravi Vij, MD, MBA Washington University Medical School, St Louis, MO, discusses toxicities of multiple myeloma (MM) drug treatments and managing these side-effects, speaking at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Ravi Vij

MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma 2:48
MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma
Ravi Vij • 11 Dec 2023
Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma 2:26
Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma
Ravi Vij • 11 Dec 2023
Updated safety and efficacy results of ABBV-383, a novel BsAb, in patients with R/R multiple myeloma 3:23
Updated safety and efficacy results of ABBV-383, a novel BsAb, in patients with R/R multiple myeloma
Ravi Vij • 11 Dec 2023
Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring 2:35
Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
Ravi Vij • 12 Dec 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals